Michael Weickert

Chief Executive Officer Pacylex Pharmaceuticals, Inc.

Michael Weickert, PhD, is a veteran biotech executive, entrepreneur, and advisor with more than 25 years of experience leading life science companies from discovery through clinical development and financing. He is CEO of Pacylex Pharmaceuticals, where he has raised over $23 million and advanced a first‑in‑class oncology drug into three Phase 2a-ready clinical programs, securing Orphan Drug and Fast Track designations. Dr. Weickert held CEO, COO, CBO, and board roles across startups and public companies, advises Stanford Medicine’s SPARK program, and supported numerous financings and partnerships. He brings deep expertise in drug development, strategy, and capital raising.

Seminars

Thursday 27th August 2026

Evaluating Clinically Validated NMT Inhibitors as ADC Payloads

11:30 am

Characterizing the mechanism of action of NMT inhibitors across tumor models, to understand their potential as highly potent ADC payloads
Assessing the preliminary clinical safety and antitumor efficacy of Zelenirstat as an oral therapeutic, to establish its therapeutic window and translational potential for payload development
Evaluating the initial performance of NMT inhibitors as ADC payloads, to determine their effects on targeted cytotoxicity, payload stability, and antitumor activity while minimizing off-target toxicities